SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (3547)12/12/1997 11:01:00 PM
From: RT  Read Replies (1) | Respond to of 23519
 
Cacaito,

During the CNBC inteview Leland said Vivus had no intention of lowering prices in the US market with the introducing of Viagara.
Since Muse's only competition in the moderate to severe ED catagory was Caverjat why discount.

RT



To: Cacaito who wrote (3547)12/13/1997 1:01:00 AM
From: blankmind  Read Replies (1) | Respond to of 23519
 
What do you mean by "before the orals are approved?"

-- Hasn't the Pfeizer drug been approved yet?

-- If not, why not?

Out.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News